

S4 Table. Comparison of clinical characteristics and response to neoadjuvant modified FOLFIRINOX according to detection of DDR gene alteration (n=25)

Characteristic	DDR gene alteration detected (n=10)	No DDR gene alteration detected (n=15)	p-value
Age (yr)			> 0.99
< 60	4 (40.0)	7 (46.7)	
≥ 60	6 (60.0)	8 (53.3)	
Sex			0.11
Male	7 (70.0)	5 (33.4)	
Female	3 (30.0)	10 (66.6)	
Primary location			0.65
Head	7 (70.0)	12 (80.0)	
Body	3 (30.0)	3 (20.0)	
Baseline CA 19-9 level (IU/mL)			0.65
< 37	3 (30.0)	3 (20.0)	
> 37	7 (70.0)	12 (80.0)	
Histopathology	7	8	0.28
Adenocarcinoma, WD	3 (42.9)	1 (12.5)	
Adenocarcinoma, MD	4 (57.1)	4 (50.0)	
Adenocarcinoma, PD	0	3 (37.5)	
Response to mFOLFIRINOX by RECIST v1.1			
Partial response	4 (40.0)	5 (33.4)	
Stable disease	6 (60.0)	9 (60.0)	
Progressive disease	0	1 (6.6)	
Objective response rate (%)	40.0	33.4	> 0.99
Proceeded to curative surgery			0.23
Yes	8 (80.0%)	8 (53.3%)	
No	2 (20%)	7 (46.7%)	

CA 19-9, carbohydrate antigen 19-9; DDR, DNA damage repair; MD, moderately differentiated; mFOLFIRINOX, modified fluorouracil, leucovorin, oxaliplatin, and irinotecan; PD, poorly differentiated; RECIST, Response Evaluation Criteria for Solid Tumor; WD, well differentiated.